Symbol | Exchange | Currency |
|---|
By Dhirendra TripathiInvesting.com – Johnson & Johnson (NYSE:JNJ) shares fell more than 1% Friday after the Food and Drug Administration asked it to throw out 60...
Emergent Biosolutions (EBS): Q1 Non-GAAP EPS of $1.53 beats by $0.36; GAAP EPS of $1.28 beats by $0.49.Revenue of $343M (+78.2% Y/Y) misses by $16.69M.For Q2 2021, the Company...
Emergent Biosolutions (NYSE:EBS) is scheduled to announce Q1 earnings results on Thursday, April 29th, after market close.The consensus EPS Estimate is $1.17and the consensus...
Broader markets are close to record highs. Year-to-date, the Dow Jones Industrial Average, the S&P 500 and the NASDAQ 100 are up around 11.5%, 11.6% and 8.2%,...
The biotech sector continues to be in focus as the development of vaccines for coronavirus continues to be the key focus. Other pipeline and regulatory updates also grabbed the...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Sell | Sell | Strong Sell | Sell |
| Technical Indicators | Buy | Strong Buy | Strong Sell | Sell | Strong Sell |
| Summary | Buy | Neutral | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 336.75 | 339.92 | 335.03 | -0.02 | -0.01% | 15.78M | NASDAQ | |||
| 2,428.39 | 2,455.51 | 2,421.12 | -20.52 | -0.84% | 1.07M | NASDAQ | |||
| 59.04 | 64.71 | 56.73 | +2.04 | +3.58% | 284.72M | NYSE | |||
| 210.06 | 214.49 | 209.64 | -3.88 | -1.81% | 12.15M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 34.96 | 34.97 | 33.99 | +1.14 | +3.37% | 3.13M | NYSE | |||
| 17.51 | 17.56 | 16.80 | +0.70 | +4.16% | 6.18M | NYSE | |||
| 7.66 | 7.79 | 7.62 | -0.10 | -1.29% | 6.55M | NYSE | |||
| 5.07 | 6.15 | 4.32 | +1.4900 | +41.62% | 263.71M | NASDAQ | |||
| 25.67 | 25.73 | 25.33 | +0.43 | +1.70% | 6.21M | NYSE | |||
| 2,520.66 | 2,537.24 | 2,512.97 | -6.38 | -0.25% | 1.11M | NASDAQ | |||
| 54.97 | 55.00 | 51.12 | +3.86 | +7.55% | 228.15K | NYSE | |||
| 29.28 | 29.30 | 29.04 | +0.19 | +0.65% | 26.20M | NYSE | |||
| 0.6933 | 0.00 | 0.00 | -0.0121 | -1.72% | 1.05M | NYSE | |||
| 69.59 | 70.95 | 69.41 | -1.32 | -1.86% | 849.79K | NYSE |
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
